The Impact of Rheumatoid Arthritis Treatments on the Modulation of Extracellular Vesicles and Other Biomarkers Involved in the Development of Lung Cancer

Patients with rheumatoid arthritis (RA) have an increased risk of lung cancer, potentially influenced by targeted therapies such as JAK inhibitors and biologics. Extracellular vesicles (EVs) are key mediators of intercellular communication and may carry biomarkers involved in oncogenesis. This study aims to compare EV concentration and molecular content in RA patients treated with different targeted therapies. The objective is to identify treatment-related differences in EV profiles that may contribute to lung cancer development and improve risk stratification.

Inclusion Criteria: * Patients receiving rheumatology care at Limoges University Hospital * Aged 18 years or over * Diagnosis of RA established in accordance with the 2010 ACR (American College of Rheumatology) / EULAR (European League Against Rheumatism) classification criteria * Patients who have been treated with a JAK inhibitor, anti-TNF agent, abatacept or anti-IL-6 for at least 1 month * Patients capable of expressing their refusal * Patients with up-to-date health insurance cover Exclusion Criteria: * Pregnant or breastfeeding women * Patients under a protective regime (guardianship, curatorship)